Vigil Neuroscience’s Post

🔬 Industry Insight: Radiopharmaceuticals Emerge as a Key Area for Investment and M&A At YOBE Ventures, we're always tracking the latest trends in investment opportunities. Recently, radiopharmaceuticals have caught our attention as a rapidly growing sector in the pharmaceutical industry. Key Developments: 1. Funding: Isotope Technologies Munich secured over $200 million in an equity round led by Temasek Holdings. 2. M&A Activity: AstraZeneca completed a $2.1 billion acquisition of Fusion Pharmaceuticals. 3. Startup Ecosystem: At least 12 private companies focused on radiopharmaceuticals have raised venture or growth funding in the past two years, totaling nearly $1.3 billion. 4. Clinical Promise: Treatments are showing potential for addressing some of humanity's most intractable diseases. This surge in investment aligns with our commitment to backing innovative companies that solve real-world problems. The radiopharmaceuticals sector combines cutting-edge science with significant market potential, making it an area ripe for smart investments. What are your thoughts on the future of radiopharmaceuticals? How do you see this impacting the broader healthcare and investment landscapes? #InvestmentTrends #Radiopharmaceuticals #VentureCapital #HealthcareInnovation #YOBEVentures

Numerous studies demonstrate the correlation between R&D investment and innovation. #pharmaceuticalcompanies, in particular, exhibit a high level of interest by allocating a substantial portion of their revenue towards R&D. AstraZeneca, as a prime example of a significant R&D investor, showcases the positive outcomes in terms of #innovation and #invention. ✔Follow the Science ✔Disciplined Investment

Regeneron joins other Pharma Collosi in starting their own Venture Investment Arm. Pfizer, Eli Lilly, Amgen, Bristol Myers Squibb, Astellas, and Novartis are all currently active in this space, with varying degrees of success. With Regeneron, $500M over 5 years ain’t nothing to scoff at. Drug development and venture investment, at a very high level, share similar risks, timelines, and associated ambiguities - and VC work also gets you early, insider access to potentially revolutionary tech and ideas. For those with the dough and the stomach for it (which Big Pharma already has), VC is a solid move. What do you think about this? With 2024 looking to be a banner year for biotech/pharma investment, are we going to see more Pharma-originating funds like this sprout up? Article link in comments.

💊 The Rise of New Pharma! 🌟 A shift is happening in the pharmaceutical industry: "New Pharma" companies are emerging and making waves, potentially crowding out established giants. According to a recent Reuters Breakingviews analysis, this transformation is driven by innovation, agility, and novel business models. Key insights: -Innovation Leadership: Smaller, agile companies are leading with cutting-edge research and innovative treatments. -Market Dynamics: The traditional dominance of Big Pharma is being challenged by these nimble competitors. -Investment Trends: Venture capital and strategic investments are increasingly favoring New Pharma, recognizing their potential to disrupt the industry. As the landscape evolves, both challenges and opportunities arise for all stakeholders in the healthcare ecosystem. #Pharma #NewPharma #BigPharma #Innovation #Healthcare #Biotech #MarketTrends #Investment #IndustryShift #PharmaceuticalIndustry #HealthcareInnovation

#Obesity - Getting Bigger. In this analysis we examine the comprehensive investment landscape concerning #GLP-1 drugs and their equivalents, highlighting both the potential opportunities and the accompanying challenges. Are #NovoNordisk and Eli Lilly still compelling investment options, or are there other viable candidates worth considering? Find out more in our Note. #Obesitydrug #EquityInvest #Equityideas

𝗘𝘅𝗰𝗹𝘂𝘀𝗶𝘃𝗲 𝗜𝗻𝘁𝗲𝗿𝘃𝗶𝗲𝘄 𝘄𝗶𝘁𝗵 𝗖𝗵𝗿𝗶𝘀𝘁𝗼𝗽𝗵 𝗕𝘂𝗲𝗿𝗸𝗶 𝗼𝗻 𝗠𝗮𝗺𝗺𝗮𝗹𝗶𝗮𝗻 𝗜𝗻𝘃𝗲𝘀𝘁𝗺𝗲𝗻𝘁 Following our Mammalian investment in Austria and Singapore, Christoph Buerki, Chief Financial Officer Operations & Head CMO shares his thoughts on what it means for Novartis Contract Manufacturing business and pharma companies.   Watch the video to gain deeper insights on how we are shaping the future of healthcare through cutting-edge technologies and partnerships.  #Mammalian #SingaporeExpansion #Novartis #ContractManufacturing   

🔍Dive into the fascinating world of pharmaceutical innovation! Did you know? It takes years of dedicated effort to bring a new drug from the laboratory to a successful launch. But the story doesn't end there - understanding the strategic positioning of the product in the market, and considering various factors to boost up your Return on Investment (ROI). On an average, it's approximately 12-year journey requiring a staggering investment and yet success is not guaranteed.   🚀Plan to embark on a journey with Virendra Kumar, Atul Banerjee and Faheem Rasheed to unravel the complexities of market research, product positioning, and competitive intelligence within the realm of pharmaceutical launches. Discover invaluable insights into how mastering these principles can propel your professional journey forward, equipping you with the knowledge and skills to navigate challenges effectively and capitalize on opportunities with confidence.

Thoughts on this? >> Investing in fast-growing biotechnology companies with BB Biotech's Dr Daniel Koller - UK Investor Magazine >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #competitivemarketing #biotech #healthcare

"Believe in yourself and dare." These are the words of Hamza Laajaj, @Sanofi’s Manufacturing 4.0 Booster Leader at our Neuville site (France), and a motto we collectively share. At Sanofi, when it comes to manufacturing vaccines to improve people’s lives, we embrace diversity through the roles we play, the projects we work on, and the teams we work with. By being open to diversity, we unlock innovation. Learn more about how Hamza is fueled by collective energy to lead manufacturing innovation in our pursuit of progress. #PursueProgress #Science #Diversity

"Believe in yourself and dare." These are the words of Hamza Laajaj, @Sanofi’s Manufacturing 4.0 Booster Leader at our Neuville site (France), and a motto we collectively share. At Sanofi, when it comes to manufacturing vaccines to improve people’s lives, we embrace diversity through the roles we play, the projects we work on, and the teams we work with. By being open to diversity, we unlock innovation. Learn more about how Hamza is fueled by collective energy to lead manufacturing innovation in our pursuit of progress. #PursueProgress #Science #Diversity